Article Text
Abstract
Background: Current best practice for treating acute severe pain in children is to administer intravenous or intranasal opioid. Intranasal diamorphine offers less traumatic analgesia than the potentially difficult and distressing intravenous route. However, there has been no direct comparison of intranasal and intravenous diamorphine nor are there pharmacokinetic data for intranasal diamorphine in children.
Objective: To compare plasma morphine concentration–time profiles following intranasal and intravenous diamorphine administration.
Design: Observational.
Setting: A&E department in a city-centre paediatric teaching hospital.
Patients: Children, aged 3–13 years, with isolated limb fracture.
Interventions: An intravenous catheter was sited and baseline blood taken. The first 12 children received intravenous diamorphine (0.1 mg/kg), and the subsequent 12 intranasal diamorphine (0.1 mg/kg) in 0.2 ml sterile water drops. Subsequent samples were taken at 2, 5, 10, 20, 30 and 60 min.
Measurements: Plasma morphine radioimmunoassay.
Results: Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann–Whitney U test). Higher plasma concentrations at 60 min (47 vs 32 nmol/l) were also observed following intravenous diamorphine (p = 0.01, Mann–Whitney U test).
Conclusions: Our evidence supports the wider use of diamorphine administration by nasal drops in children, as it shows that adequate plasma levels of morphine are usually achieved. However, we demonstrated significantly attenuated and delayed peak plasma morphine levels with lower levels at 1 h with intranasal compared with intravenous diamorphine.
Statistics from Altmetric.com
Footnotes
Funding This project was funded by a grant from the British Association of Emergency Medicine, and the Research & Development Department, Lothian Universities Hospital Trust. Diagnostic Products Corporation donated one of the RIA kits. The funding bodies played no part in study design; in the collection, analysis, and interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication.
Competing interests None.
Ethics approval Ethics approval was obtained from the Lothian regional ethics committee.
Patient consent Parental consent obtained.
Provenance and peer review Not commissioned; not externally peer reviewed.